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REVIEW
What should you know about limbic 
encephalitis?
O que deve saber sobre encefalites auto-imunes?
Sara Machado1,2, Amélia Nogueira Pinto1, Sarosh R. Irani3
Limbic encephalitis was firstly described by Brierley in 
19601 and was characterized as an inflammatory disorder in-
volving the hippocampi, amygdala, frontobasal and insular re-
gions, with a spectrum of symptoms, most commonly charac-
terized by a subacute progressive impairment of short-term 
memory, psychiatric features and seizures. While in some 
cases it appears to exclusively involve limbic regions, it has be-
come clear that several clinical features implicate involvement 
of areas other than the limbic system. For this reason, the au-
thors prefer the term autoimmune encephalitis (AIE).
Once regarded as a rare and paraneoplastic disorder with 
a poor prognosis, most forms of AIE are now recognised as 
being non-paraneoplastic and a substantial proportion of 
them may have a good response to immunotherapy, particu-
larly if it is promptly initiated.
Due to a broad differential diagnosis, the recognition of 
AIE is frequently difficult and delayed. The aim of this article 
was to facilitate recognition of the clinical features and to 
simplify the diagnostic approach, with the ultimate objective 
of rapid immunotherapy administration.
CLINICAL VIGNETTE
A 52-year-old, right handed, man presented to the 
Accident and Emergency (A&E) department after two gen-
eralized tonic-clonic seizures. He was previously healthy and 
was the third of four healthy siblings with no problems dur-
ing development or birth. He was successful at school and 
worked as a lawyer. There was no previous history of epilepsy, 
infections of the central nervous system (CNS), trauma, sub-
stance abuse or smoking. He was a moderate consumer of al-
cohol and was taking no medications. There was no relevant 
family history. 
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ABSTRACT
Autoimmune encephalitis is an inflammatory disorder characterized by a subacute impairment of short-term memory, psychiatric features 
and seizures. It is often associated with a variety of other neurological symptoms, and its differential diagnosis is wide, leading to challenges 
in its recognition. It used to be regarded as a rare disease, usually paraneoplastic and with poor prognosis. However, with the recent recogni-
tion of membrane-surface directed antibodies, it is now known that in a substantial proportion of cases there is no association with any ma-
lignancy and there is a good prognosis if treated. Hence, early recognition and prompt initiation of immunotherapies are of great importance.
Key words: limbic autoimmune encephalitis, encephalopathy, intracellular antigens, membrane surface antigens, VGKC-complex, LGI1, 
CASPR2, N-methylaspartate, paraneoplastic syndrome, immunotherapy.
RESUMO
A encefalite autoimune é uma doença inflamatória caracterizada por envolvimento subagudo da memória de curto prazo, presença de sin-
tomas psicóticos e crises epilépticas. Dada a diversidade de sintomas na apresentação, o diagnóstico diferencial é um verdadeiro desafio. 
Anteriormente, era considerada uma doença rara, de etiologia paraneoplásica e com mau prognóstico. No entanto, com a recente descoberta 
dos anticorpos dirigidos à superfície da membrana, é atualmente reconhecido que uma grande parte dos casos não tem uma neoplasia sub-
jacente e apresenta um ótimo prognóstico. Assim, o diagnóstico e tratamento imunoterápico precoces são de extrema importância.
Palavras-Chave: encefalite límbica autoimune, encefalopatia, antigénios intracelulares, antigénios da superfície de membrana, complexo 
VGKC, LGI1, CASPR, N-metilaspartato, síndrome paraneoplásica, imunoterapia. 
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His spouse noticed that over the last two months he had 
developed irritability and forgetfulness, which was associ-
ated with frequent involuntary jerks of the right side of the 
face and ipsilateral arm. There was no fever or headache. On 
examination, he was confused and showed a marked defi-
cit in anterograde memory. After a normal Computerized 
Tomography (CT) scan, he was treated with acyclovir and 
phenytoin. Despite this, ongoing jerks were noted.
The differential diagnosis of this case is discussed in the 
Table 12-4 and the results of investigation in Table 2.
Given the subacute history of cognitive decline and the 
presence of focal seizures (likely faciobrachial dystonic sei-
zures) along with the MRI changes, AIE was suspected5,6. Also 
taking into consideration the age of the patient, a normal 
CSF and serum hyponatremia, antibodies against the VGKC-
complex7 were requested, and the results were strongly posi-
tive. A body CT showed no underlying neoplasm. The patient 
was treated with high-dose steroids and made a good recov-
ery, returning to work after four months.
The key points for the definite diagnosis were:
 (1) subacute history of cognitive decline, irritability and 
seizures that were refractory to antiepileptic drugs;
 (2) presence of faciobrachial dystonic seizures, which 
are highly characteristic of antibodies against the  LGI1 
(leucine-rich glioma inactivated 1) subunit of the 
VGKC-complex;
 (3) MRI with medial temporal abnormalities in associa-
tion with a normal CSF evaluation;
 (4) serum hyponatremia without an alternative 
explanation.
In the next sections, cardinal clinical signs will be presented ac-
cording to each underlying antibody, and a diagnostic approach 
will be proposed in order to facilitate the clinical recognition of AIE.
DESCRIPTION
Pathophysiology
For all AIE, a division can be made regarding the location 
of the causal antigens and, therefore, likely disease mecha-
nisms. Generally, antibodies to intracellular antigens are 
associated with underlying malignancies and, in contrast, 
those against membrane antigens usually do not reflect the 
presence of a tumour. However, some membrane autoanti-
bodies may be associated with tumours (Fig 1). Hence, in all 
patients presenting with suspected AIE, a comprehensive 
search for an underlying malignancy is considered.
Antibodies to intracellular antigens (inside the neu-
ron) – Hu, Ma2, CV2, Antiphiphysin, glutamic acid de-
carboxylase (GAD)
Diagnosis Possible distinguishing features
Viral encephalitis: commonly Herpes simplex virus More abrupt onset, fever, headache
MRI: typically extensive hippocampal involvement, often with haemorrhagic lesions.
Creudtzfeldt-Jakob disease Rapidly progressive dementia, myoclonus, visual hallucinations, psychiatric disturbance.
MRI: pulvinar and cortical lesions, but may show mesial temporal lobe changes 
mimicking AIE2. EEG: periodic sharp wave complexes.
Metabolic/Toxic encephalopathy Wernicke-Korsakoff Syndrome: history of alcohol intake and prominent confabulation.
Specific MRI features
Tumour Glioma or primary lymphoma of the CSN. Focal signs are frequent.
Autoimmune meningoencephalopathies e.g. Sjogrens, SLE, Behçets. 
Commonly show systemic involvement.
Neurosyphilis Slow progression, Argyll Robertson pupils. 
MRI: may show mesial temporal lobe changes3,4.
Degenerative: Alzheimer disease Longer course is typical, mostly without seizures.
Table 1. Differential diagnosis. 
MRI: Magnetic Resonance Imaging; AIE: autoimmune encephalitis; EEG: Electroencephalogram; CSN: central nervous system; SLE: systemic lupus 
erythematosus.
Investigations Results
Blood analysis FBC, renal and thyroid function, hepatic enzymes + serological panel for autoimmune 
disorders: ESR, CRP, complement levels, ANA, dsDNA, ANCA, ACE, SS-A, SS-B, RF, 
cardiolipin, anti-thyroid antibodies, serum protein electrophoresis – unremarkable.
Hyponatraemia 128 mmol/L, urine sodium 60 mmol/L
Cranial computed tomography (CT) Unremarkable
Cranial magnetic resonance imaging (MRI) T2 and FLAIR hyperintense lesions in the left medial temporal lobe, without 
haemorrhagic lesions
Electroencephalogram (EEG) Mild diffuse slow activity 
Cerebrospinal fluid (CSF) Normal. No inflammatory changes (neither pleocytosis nor oligoclonal bands)
FBC: full blood count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ANA: anti- nuclear antibodies; ANCA: anti-neutrophil cytoplasmi cantibody; 
dsDNA: double-stranded deoxyribonucleic acid; ACE: angiotensin-converting enzyme; SS-A and SS-B: Sjögren’s syndrome A and B; RF: rheumatoid factor. 
Table 2. Results of investigations.
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These are usually associated with cytotoxic T cell mecha-
nisms. The neuronal damage seems to be irreversible and the 
prognosis is usually poor. One exception appears to exist in 
patients with GAD antibodies: these patients may have AIE, 
epilepsy or other neurological syndromes, tumours are un-
common, and recovery is possible although patients are of-
ten less responsive to immunotherapies5.
Antibodies to cell membrane surface antigens – 
VGKC-complex (LGI1, CASPR2, contactin-2) and the 
NMDA, AMPA, GABAB and Glycine receptors
This increasingly recognised category is much less fre-
quently associated with malignancy, and the neurological 
disease is thought to be mediated by the antibodies them-
selves. These diseases tend to have a better response to im-
munotherapy. The first recognised syndrome in this category 
was the VGKC-complex antibody syndrome8.
CLINICAL PICTURE
The cardinal signs of AIE are the impairment of short-term 
memory, usually developing over weeks or months, psychiat-
ric symptoms (irritability, depression and hallucinations) and 
mesiotemporal seizures5-9. Apart from this typical “limbic syn-
drome”, there are other associated neurological features, which 
often reflect the presence of different associated antibodies.
Antibodies to intracellular antigens 
Hu (ANNA-1) – this type can involve any part of the ner-
vous system, including peripheral nerves, dorsal root ganglia 
and spinal cord. A smoking history is often present as 75% of 
patients have small cell lung carcinoma (SCLC)10. The prog-
nosis is usually poor despite immunotherapy.
Ma2 – the clinical clues are the presence of both hypo-
thalamic (daytime sleepiness, narcolepsy, cataplexy, hyper-
phagia, hormonal deficits) and brainstem dysfunction (par-
ticularly with supranuclear gaze palsy)11. It occurs mostly in 
association with testicular germinal cell tumour in younger 
males, but in older individuals there may be an underlying 
non-small cell lung carcinoma or breast cancer12. Men with 
Ma2-antibody encephalitis in whom there is no detectable 
testicular tumour may have a microscopic tumour below the 
detection threshold of imaging techniques. For this reason, 
orchidectomy may be necessary in face of clinical deterio-
ration, de novo testicular enlargement, previous cryptorchi-
dism or ultrasound evidence of testicular microcalcification, 
in the absence of other tumours8. MRI may show contrast 
enhancement13.
CV2 – the presence of chorea14 is highly suggestive. It may 
also occur with involvement of other systems, commonly the 
visual system (uveitis, optic neuritis). There may be an under-
lying SCLC, malignant thymoma or other tumours.
GAD – although GAD is an intracellular enzyme, antibod-
ies directed against this enzyme are usually associated with a 
non-paraneoplastic AIE15-17. It tends to occur in women without 
any identified tumour. Drug resistant epilepsy is common15 and 
GAD-antibodies are also associated with the stiff-person syn-
drome and ataxia16. These antibodies are very common in other 
autoimmune disorders, typically DM1, often at lower levels15-18.
Antibodies to cell membrane antigens
The most common syndromes
NMDAR – this appears to be one of the most frequent AIE19. 
It was initially described in young women with ovarian terato-
mas20, of which 70% were benign. Nevertheless, it is now known 
that it also frequently affects men and children21. The presence 
of a tumour is more frequent in black women older than 18 
years19 and rare in paediatric populations. The characteristic 
clinical picture starts with a psychotic stage (many patients are 
initially seen by psychiatrists) and seizures, followed by reduc-
tion in consciousness, autonomic instability (which includes 
fluctuation of blood pressure  and  temperature, tachycardia, 
bradycardia, cardiac pauses and diaphoresis) and movement 
disorders, namely dyskinesias. The oral-lingual-facial dyskine-
sias19 are the most characteristic, but other abnormal move-
ments, such as opisthotonic postures and a catatonic state22, 
may also occur. A curious feature is a dissociative response to 
stimuli: patients may resist eye opening, but show reduced or 
absent response to painful stimuli23. Invasive ventilation and 
admission to an intensive care unit are frequently necessary. 
Fig 1. Antibody targets associated with non-paraneoplastic 
and paraneoplastic syndromes. Although most commonly 
associated with intracellular antibodies, paraneoplastic 
syndromes may also be caused by membrane antibodies. 
Hence, even in the presence of membrane antibodies, a search 
for an underlying malignancy should be considered.
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Disease relapses may occur in 15–25% of cases, especially in 
non-paraneoplastic cases without adequate immunotherapy 
during their previous encephalitic episode21,24,25. As far as inves-
tigations are concerned, CSF typically reveals an early lympho-
cytic pleocytosis followed by intrathecal synthesis of antibod-
ies21,26. The MRI is frequently normal, however changes can be 
seen in medial temporal lobes and in white matter19,21.
VGKC-complex (LGI1, CASPR2, Contactin-2) – it has been re-
cently recognized that VGKC antibodies are directed to particu-
lar components of the VGKC-complex, most commonly LGI1, 
CASPR2 and Contactin-25,6,27. In VGKC-complex associated 
AIE, most antibodies are directed against LGI1, but a minority 
have CASPR2 antibodies5. Patients show a male:female ratio of 
2:1 and are typically older than 40 years27. This encephalitis may 
also present with rapid eye movement sleep behaviour disorder, 
hypothermia28, startle syndrome, ataxia and intestinal pseudo-
obstruction. A recently described and highly distinctive feature 
is the presence of faciobrachial dystonic seizures (FBDS), char-
acterized by brief and frequent dystonic paroxysms typically in-
volving the face and ipsilateral arm; these patients consistently 
have antibodies against LGI16. In VGKC-complex antibody AIE, 
MRI typically reveals hyperintensity best appreciated in T2 and 
FLAIR sequences in the mesiotemporal lobes. However, around 
40% of cases have a normal MRI27, and the CSF tends to show 
the absence of pleocytosis or intrathecal synthesis. Another dis-
tinguishing feature is the presence of hyponatremia in around 
50% of cases, usually with a SIADH pattern. Only a few VGKC-
complex antibody positive patients have tumours, typically 
SCLC or thymoma26. In contrast to NMDAR-antibody positive 
patients, relapses are unusual in those with antibodies against 
VGKC-complexes. Patients with an encephalopathy and prom-
inent insomnia, neuromyotonia and dysautonomia are often 
termed Morvan’s syndrome. These patients show high levels of 
CASPR2-antibodies, often with lower levels of LGI1-antibodies29. 
Morvan’s patients have a high risk of an underlying tumour 
which is usually a thymoma: the majority of patients with a tu-
mour have CASPR2 antibodies29.
Less frequent syndromes
AMPAR – this antibody has been identified in women 
with relapsing AIE. Of patients, 64% had an underlying tu-
mour, and the SCLC are the most common18,30. CSF typically 
shows pleocytosis and intrathecal synthesis of antibodies.
GABABR – clinically fairly typical apart from early and promi-
nent epileptic seizures5. Despite being membrane antibodies, 
they have been reported to commonly associate with SCLC31.
GlycineR – patients may present with progressive enceph-
alomyelitis with rigidity and myoclonus (PERM)24, a rare con-
dition showing limb and axial rigidity, muscle spasms, brain-
stem signs and hyperekplexia32-34. Investigations may show 
CSF with inflammatory changes, and MRI has been normal 
in all of the published clinical reports33,34.
mGluR5 – the two published cases had Hodgkin 
lymphoma (ophelia syndrome). The clinical picture is 
reasonably typical, the CSF shows pleocytosis and MRI, 
apart from limbic involvement, may show parietal and oc-
cipital cortex changes35.
DIAGNOSIS
AIE has a wide differential diagnosis. One way of trying 
narrow-down the possibilities is to create a rational plan of 
investigations guided by an accurate clinical history, in an at-
tempt to identify the key points already described. 
As far as the diagnosis is concerned, the first step is to 
consider other treatable disorders, such as viral encephali-
tis and systemic autoimmune diseases. Secondly, the basic 
workup includes the following investigations: 
 (1) MRI – signal changes of medial temporal lobes, best 
seen in T2 and FLAIR sequences. Often no changes are 
seen on MRI.
 (2) CSF – typically with inflammatory changes as lym-
phocytic pleocytosis, high protein and oligloconal bands. 
However, in many conditions, these changes are not present.
 (3) EEG – often showing diffuse slowing and some-
times more focal or epileptiform changes.
 (4) A comprehensive investigation to exclude an under-
lying neoplasm should be considered in all cases. 
The combination of the clinical picture and the above 
laboratory investigations often suggests the diagnosis of AIE, 
but normal results do not exclude it (particularly normal CSF 
analysis and MRI). Brain fluorodeoxyglucose PET scan may 
be useful as it may show hypermetabolic changes in the tem-
poral lobes when the MRI is still normal21,36.
One should bear in mind that in 60–70% of the paraneo-
plastic cases, the neurological picture precedes the symptoms 
related to the cancer. One valuable approach is screening with 
body imaging such as a CT and/or a PET scan. Additionally, 
testicular ultrasound in men and mammography/mammary 
ultrasound in women should be performed when appropriate. 
The final step is to detect the autoantibodies either in se-
rum or CSF. In almost all patients, serum shows higher con-
centrations of antibodies than CSF. It is worth discussing 
the preferred sample with your diagnostic laboratory as the 
methods of detection may determine the sample of choice37. 
As there is a constant discovery of new antibodies and an in-
creasing heterogeneity regarding the clinical picture, it may 
be tricky to decide which antibody to test. Both past med-
ical history and clinical presentation are critical in guiding 
the optimal approach. There are features that help to distin-
guish subtypes, for example, hyponatremia ad initium (a con-
sequence of the syndrome of inappropriate ADH secretion) 
and acellular CSF in VGKC-complex antibody mediated en-
cephalitis and the combination of a normal MRI and severe 
encephalopathy with a movement disorder in NMDAR anti-
body patients. 
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Different diagnostic criteria have already been pro-
posed7,9,38,39 and the aim of the following diagram (Fig 2) was 
to simplify the diagnostic workup. Its rationale is to firstly ex-
clude alternative treatable conditions (such as herpes sim-
plex encephalitis) and, secondly, to determine which anti-
body is likeliest given the clinical phenotype. 
TREATMENT
When autoimmune encephalitis is considered likely, 
treatment should be started promptly. Also, a trial of immu-
notherapy may serve as a valuable “diagnostic test”. However, 
some conditions are typically refractory to initial immuno-
therapy administration (e.g. NMDAR-antibody encephalitis), 
and the trial should not be considered definitive proof as to 
the immune aetiology of the illness. 
If there is an identified neoplasm, its removal may be im-
portant for the neurological improvement7,20,21. However, in 
traditional paraneoplastic cases associated with intracellu-
lar antibodies, there is rarely a favourable response to this 
approach even with immunotherapies. On the other hand, 
those cases of AIE associated with membrane antibodies 
may have a good response to immune interventions, plus 
tumour removal when indicated20,26. IVIg, plasma exchange 
(PE), corticosteroids, cyclophosphamide and rituximab have 
all been used with success.
A typical strategy for acute therapy is IV methylpredniso-
lone (1 g IV daily for 3–5 days) with either IVIG (0,4–1 g/kg IV 
daily for 3–5 days) or PE, usually followed by oral predniso-
lone. If there is no or only a limited response, some authors 
advocate second-line therapies20, such as rituximab and/or 
cyclophosphamide.
FINAL REMARKS
AIE is a relatively frequent inflammatory disorder with 
protean clinical manifestations in addition to a typical “lim-
bic syndrome”, reflecting the diverse likely causal antibodies. 
Antibodies against intracellular antigens tend to be associ-
ated with underlying malignancies. On the other hand, those 
directed to membrane antigens are usually not associated 
with tumours and have a better prognosis. However, such 
categorization is somewhat artificial, because membrane au-
toantibodies may also be associated with tumours. 
As there are so many associated neurological symptoms, an 
accurate clinical history is mandatory for the correct investigation 
of the underlying autoantibody. Many of the clinical and investiga-
tion features strongly predict the underlying antibody and hence 
the association with tumours and potential response to immuno-
therapies. There are some precious clues, as the presence of hypo-
natremia and faciobrachial dystonic seizures with VGKC complex 
antibodies or psychiatric onset, movement disorders and dissocia-
tive responses with NMDAR antibodies. The phenotype may help 
clinicians to make a rational decision regarding antibody testing. 
The identification of an encephalopathy with an autoim-
mune pathogenesis and, therefore, a potential response to 
immunotherapy is of great importance as successful treat-
ments are possible. Notwithstanding, pharmacological man-
agement remains empirical, and prospective studies are 
needed to determine the optimal drug regimen.
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Fig 2. Proposed diagnostic approach for autoimmune encephalitis.
DIAGNOSTIC APPROACH OF AUTOIMMUNE ENCEPHALITIS
STEP 1: Exclusion of treayable causes such as Herpes simplex encephalitis and systemic autoimmune diseases.
POSSIBLE AUTOIMMUNE ENCEPHALITIS?
STEP 2: Is it an autoimmune encephalitis? Accurate history and examination.
STEP 3: Is there an underlying malignancy? Consider comprehensive search according to the clinical context.
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CSF: cerebrospinal fluid; GAD: glutamic acid decarboxylase; MRI: magnetic resonance imaging; CT: computed tomography; CRP: C-reactive protein; ESR: 
erythrocyte sedimentation rate; ANA: anti- nuclear antibodies; ANCA: anti-neutrophil cytoplasmic antibody; US: ultrasound; AIE: autoimmune encephalitis.
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